Xeris Pharmaceuticals
Stage
IPO | IPOTotal Raised
$153.58MDate of IPO
6/21/2018Market Cap
0.24BStock Price
1.79About Xeris Pharmaceuticals
Xeris is a specialty biopharmaceutical company focused on developing improved and differentiated injectable therapeutics for multiple indications in diabetes, epilepsy, and immunology. The company's XeriSol and XeriJect formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using auto-injectors, multi-dose pens, and pumps.
Xeris Pharmaceuticals Headquarter Location
180 N LaSalle St Suite 1800
Chicago, Illinois, 60601,
United States
844-445-5704
Expert Collections containing Xeris Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Xeris Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Diabetes
1,750 items
Xeris Pharmaceuticals Patents
Xeris Pharmaceuticals has filed 30 patents.
The 3 most popular patent topics include:
- Amines
- Diabetes
- G protein coupled receptors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/6/2015 | 9/28/2021 | Medical equipment, Drug delivery devices, Dosage forms, Fluid dynamics, Pharmacokinetics | Grant |
Application Date | 8/6/2015 |
|---|---|
Grant Date | 9/28/2021 |
Title | |
Related Topics | Medical equipment, Drug delivery devices, Dosage forms, Fluid dynamics, Pharmacokinetics |
Status | Grant |
Latest Xeris Pharmaceuticals News
May 10, 2022
Xeris Pharmaceuticals (NASDAQ: XERS ) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is -$0.24 (+20.0% Y/Y) and the consensus Revenue Estimate is $23.39M (+190.6% Y/Y). Over the last 2 years, XERS has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 1 downward. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Xeris Pharmaceuticals Web Traffic
Xeris Pharmaceuticals Rank
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.